any assets drawn down as withdrawals from a bank, the sale of property, a house, or a car; or tax refunds, gifts, loans, lump-sum inheritances, one-time insurance payments, or compensation for injury. Also excluded are noncash benefits, such as the employer-paid or union-paid portion of health insurance or other employee fringe benefits, food or housing received in lieu of wages, the value of food and fuel produced and consumed on farms, the imputed value of rent from owner-occupied nonfarm or farm housing, and such Federal noncash benefit programs as Medicare, Medicaid, food stamps, school lunches, and housing assistance.

Dated: February 27, 1996.

Donna E. Shalala,

Secretary of Health and Human Services.

[FR Doc. 96–4915 Filed 2–29–96; 10:52 am]

BILLING CODE 4150–04–P

Federal Financial Participation in State Assistance Expenditures; Federal Matching Shares for Aid to Families With Dependent Children, Medicaid, and Aid to Needy Aged, Blind, or Disabled Persons for October 1, 1996 Through September 30, 1997

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: The Federal Percentages and Federal Medical Assistance Percentages for Fiscal Year 1997 have been calculated pursuant to the Social Security Act (the Act). These percentages will be effective from October 1, 1996 through September 30, 1997. This notice announces the calculated ''Federal percentages'' and ''Federal medical assistance percentages'' that we will use in determining the amount of Federal matching in State welfare and medical expenditures. The table gives figures for each of the 50 States, the District of Columbia, Puerto Rico, the Virgin Islands, Guam, American Samoa, and the Northern Mariana Islands. Programs under title XIX of the Act exist in each jurisdiction; title IV–A programs exist in all jurisdictions except American Samoa and the Northern Mariana Islands; programs under titles I, X, and XIV operate only in Guam and the Virgin Islands; while a program under title XVI (AABD) operates only in Puerto Rico. The percentages in this notice apply to State expenditures for assistance payments and medical services (except family planning which is subject to a higher matching rate). The statute provides separately for Federal matching of administrative costs.

Sections 1101(a)(8) and 1905(b) of the Act, as revised by section 9528 of Public Law 99–272, require the Secretary of Health and Human Services to publish these percentages each year. The Secretary is to figure the percentages, by formulas in sections 1101(a)(8) and 1905(b) of the Act, from the Department of Commerce's statistics of average income per person in each State and in the National as a whole. The percentages are within upper and lower limits given in those two sections of the Act. The statute specifies the percentages to be applied to Puerto Rico, the Virgin Islands, Guam, American Samoa, and the Northern Mariana Islands.

The ''Federal percentages'' are for Aid to Families with Dependent Children (AFDC) and aid to needy aged, blind, or disabled persons, and the ''Federal medical assistance percentages'' are for Medicaid. However, under section 1118 of the Act, States with approved Medicaid plans may claim Federal matching funds for expenditures under approved State plans for these other programs using either the Federal percentage or the Federal medical assistance percentage. These States may claim at the Federal medical assistance percentage without regard to any maximum on the dollar amounts per recipient which may be counted under paragraphs (1) and (2) of sections 3(a), 403(a), 1003(a), 1403(a), and 1603(a) of the Act.

DATES: The percentages listed will be effective for each of the 4 quarter-year periods in the period beginning October 1, 1996 and ending September 30, 1997.

FOR FURTHER INFORMATION CONTACT:

Mr. Gene Moyer, Office of Health Policy, Office of the Assistant Secretary for Planning and Evaluation, Room 442E Hubert H. Humphrey Building, 200 Independence Avenue SW, Washington, D.C. 20201, Telephone (202) 690–7861.

(Catalog of Federal Domestic Assistance Program Nos. 93.560—Assistance Payments—Maintenance Assistance (State Aid); 93.778—Medicaid Assistance Program)

Dated: February 26, 1996.

Donna Shalala,

Secretary of Health and Human Services.

FEDERAL PERCENTAGES AND FEDERAL MEDICAL ASSISTANCE PERCENTAGES, EFFECTIVE OCTOBER 1, 1996–SEPTEMBER 30, 1997 (FISCAL YEAR 1997)

State	Federal percentages	Federal medical assistance percentages
Alabama	65.00	69.54
Alaska	50.00	50.00
American Samoa	50.00	*50.00
Arizona	61.70	65.53
Arkansas	65.00	73.29
California	50.00	50.23
Colorado	50.00	52.32
Connecticut	50.00	50.00
Delaware	50.00	50.00
District of Columbia	50.00	50.00
Florida	50.88	55.79
Georgia	57.24	61.52
Guam	50.00	*50.00
Hawaii	50.00	50.00
Idaho	64.41	67.97
Illinois	50.00	50.00
Indiana	57.31	61.58
Iowa	58.83	62.94
Kansas	54.30	58.87
Kentucky	65.00	70.09
Louisiana	65.00	71.36
Maine	59.69	63.72
Maryland	50.00	50.00
Massachusetts	50.00	50.00
Michigan	50.22	55.20
Minnesota	50.00	53.60
Mississippi	65.00	77.22
Missouri	55.60	60.04
Montana	65.00	69.01
Nebraska	54.59	59.13
Nevada	50.00	50.00
New Hampshire	50.00	50.00
New Jersey	50.00	50.00
New Mexico	65.00	72.66
New York	50.00	50.00
North Carolina	59.88	63.89
North Dakota	64.14	67.73
Northern Mariana Islands	50.00	*50.00
Ohio	54.76	59.28
Oklahoma	65.00	70.01
Oregon	56.14	60.52
Pennsylvania	50.00	52.85
Puerto Rico	50.00	*50.00
Rhode Island	50.00	53.90
South Carolina	65.00	70.43
South Dakota	60.99	64.89
Tennessee	60.64	64.58
Texas	58.40	62.56
Utah	65.00	72.33
Vermont	56.72	61.05
Virgin Islands	50.00	*50.00
Virginia	50.00	51.45
Washington	50.00	50.52
West Virginia	65.00	72.60
Wisconsin	54.44	59.00

FEDERAL PERCENTAGES AND FEDERAL MEDICAL ASSISTANCE PERCENTAGES, EFFECTIVE OCTOBER 1, 1996–SEPTEMBER 30, 1997 (FISCAL YEAR 1997)—Continued

State	Federal percentages	Federal medical assistance percentages
Wyoming	55.42	59.88

*For purposes of section 1118 of the Social Security Act, the percentage used under titles I, X, XIV, and XVI and Part A of title IV will be 75 per centum.

[FR Doc. 96–4870 Filed 3–1–96; 8:45 am]

BILLING CODE 4110–60–M

Food and Drug Administration

[Docket No. 96N–0049]

Drug Export; Abbott MATRIX HCV 2.0

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Abbott Laboratories has filed an application requesting approval for the export of the human biological product Abbott MATRIX HCV 2.0 to Australia, New Zealand, and to The Federal Republic of Germany solely for the purpose of further export to Austria, Belgium, Denmark, Finland, Iceland, Ireland, Italy, The Netherlands, Norway, Portugal, Spain, Sweden, and The United Kingdom.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human biological products under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: Cathy E. Conn, Center for Biologics Evaluation and Research (HFM–610), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–594–2006.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of human biological products that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the Federal Register within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that Abbott Laboratories, One Abbot Park Rd., Abbott Park, IL 60064, has filed an application requesting approval for the export of the human biological product Abbott MATRIX HCV 2.0 to Australia, New Zealand, and to The Federal Republic of Germany solely for the purpose of further export to Austria, Belgium, Denmark, Finland, Iceland, Ireland, Italy, The Netherlands, Norway, Portugal, Spain, Sweden, and The United Kingdom. The Abbott MATRIX HCV 2.0 is an in vitro immunodot assay which has been developed to qualitatively detect antibodies to putative structural and nonstructural proteins expressed from the HCV genome in human serum or plasma. The application was received and filed in the Center for Biologics Evaluation and Research on January 24, 1996, which shall be considered the filing date for purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch (address above) in two copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. These submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

The agency encourages any person who submits relevant information on the application to do so by March 14, 1996, and to provide an additional copy of the submission directly to the contact person identified above, to facilitate consideration of the information during the 30-day review period.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Biologics Evaluation and Research (21 CFR 5.44).

Dated: January 26, 1996.

James C. Simmons,

Director, Office of Compliance, Center for Biologics Evaluation and Research.

[FR Doc. 96–4859 Filed 3–1–96; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 96N–0064]

Drug Export; Acellular Pertussis Toxoid Adsorbed

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that AMVAX, Inc., has filed an application requesting approval for the export of the human biological product Acellular Pertussis Toxoid Adsorbed to Denmark for further shipment to Sweden.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human biological products under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: Cathy E. Conn, Center for Biologics Evaluation and Research (HFM–610), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–594–2006.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of human biological products that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the Federal Register within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that AMVAX, Inc., 12103 Indian Creek Ct., Beltsville, MD 20705, has filed an application requesting approval for the export of the human biological